PriceTargets.com logo

Codexis - CDXS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.80
  • Forecasted Upside: 142.86%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.80 As of 04/24/2024 01:00 AM ET
▼ -0.1 (-3.45%)

This chart shows the closing price for CDXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Codexis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXS

Analyst Price Target is $6.80
▲ +142.86% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is $6.80, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 142.86% upside from the last price of $2.80.

This chart shows the closing price for CDXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Codexis. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/29/2024BenchmarkUpgradeHold ➝ Buy$9.00Low
11/7/2023BenchmarkDowngradeBuy ➝ HoldLow
11/6/2023Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $10.00Low
9/1/2023BenchmarkReiterated RatingBuy ➝ Buy$9.00Low
8/14/2023Stifel NicolausLower TargetBuy ➝ Buy$9.00 ➝ $5.00Low
8/7/2023TD CowenDowngradeOutperform ➝ Market Perform$21.00 ➝ $4.00Low
7/21/2023StephensReiterated RatingOverweight ➝ Overweight$6.00Low
5/9/2023BenchmarkLower Target$15.00 ➝ $9.00Low
5/9/2023HC WainwrightDowngradeBuy ➝ NeutralLow
4/17/2023Piper SandlerLower TargetOverweight$21.00 ➝ $14.00Low
2/27/2023HC WainwrightLower Target$15.00 ➝ $9.00Low
1/19/2023Piper SandlerBoost TargetOverweight$22.00 ➝ $23.00Low
11/7/2022HC WainwrightLower TargetBuy$25.00 ➝ $15.00Low
8/8/2022HC WainwrightLower TargetBuy$27.00 ➝ $25.00Low
7/19/2022BenchmarkSet Target$20.00Low
7/18/2022HC WainwrightLower Target$38.00 ➝ $27.00Low
7/15/2022Craig HallumLower Target$42.00 ➝ $19.00Low
7/15/2022CowenLower TargetOutperform$39.00 ➝ $21.00Low
7/15/2022CowenLower Target$39.00 ➝ $21.00Low
7/14/2022Piper SandlerLower TargetOverweight$35.00 ➝ $22.00Low
3/2/2022CowenInitiated CoverageBuy$39.00Low
2/25/2022HC WainwrightReiterated RatingBuy$38.00High
11/5/2021HC WainwrightBoost TargetBuy$33.00 ➝ $38.00High
10/15/2021HC WainwrightBoost TargetBuy$28.00 ➝ $33.00Low
10/14/2021CowenBoost TargetOutperform$25.00 ➝ $32.00Low
10/1/2021Craig HallumReiterated RatingBuy$30.00Low
8/6/2021HC WainwrightBoost TargetBuy$27.00 ➝ $28.00Medium
8/6/2021Piper SandlerBoost TargetOverweight$32.00 ➝ $34.00High
6/18/2021Stifel NicolausReiterated RatingBuy$30.00High
6/18/2021HC WainwrightBoost TargetBuy$27.00High
4/12/2021Piper SandlerInitiated CoverageOverweight$32.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$30.00Low
2/26/2021HC WainwrightBoost TargetBuy$21.00 ➝ $26.00High
12/30/2020BenchmarkBoost TargetBuy$21.00 ➝ $29.00N/A
8/7/2020HC WainwrightReiterated RatingBuy$21.00High
7/15/2020StephensInitiated CoverageOverweight$16.00High
5/11/2020HC WainwrightLower TargetBuy$22.50 ➝ $21.00High
3/10/2020BenchmarkInitiated CoverageBuyHigh
2/28/2020HC WainwrightReiterated RatingBuy$22.50High
12/24/2019HC WainwrightReiterated RatingBuy$22.50High
8/8/2019HC WainwrightReiterated RatingBuy$22.50Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Codexis logo
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $2.80
Low: $2.75
High: $2.91

50 Day Range

MA: $3.32
Low: $2.69
High: $4.65

52 Week Range

Now: $2.80
Low: $1.45
High: $4.91

Volume

213,453 shs

Average Volume

558,127 shs

Market Capitalization

$196.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Codexis?

The following Wall Street research analysts have issued reports on Codexis in the last year: Benchmark Co., HC Wainwright, Piper Sandler, Stephens, Stifel Nicolaus, StockNews.com, and TD Cowen.
View the latest analyst ratings for CDXS.

What is the current price target for Codexis?

5 Wall Street analysts have set twelve-month price targets for Codexis in the last year. Their average twelve-month price target is $6.80, suggesting a possible upside of 142.9%. Piper Sandler has the highest price target set, predicting CDXS will reach $10.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $4.00 for Codexis in the next year.
View the latest price targets for CDXS.

What is the current consensus analyst rating for Codexis?

Codexis currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CDXS.

What other companies compete with Codexis?

Other companies that are similar to Codexis include Century Therapeutics, Organigram, X4 Pharmaceuticals, Design Therapeutics and Rigel Pharmaceuticals. Learn More about companies similar to Codexis.

How do I contact Codexis' investor relations team?

Codexis' physical mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company's listed phone number is (650) 421-8100 and its investor relations email address is [email protected]. The official website for Codexis is www.codexis.com. Learn More about contacing Codexis investor relations.